Table 1.
Patient demographics
| T + P (n = 68) | T + C (n = 70) | |
|---|---|---|
| Sex, n (%) | ||
| Male | 53 (77.9) | 54 (77.1) |
| Female | 15 (22.1) | 16 (22.9) |
| Age (years), mean (SD) | 56.0 (9.5) | 58.4 (8.9) |
| Diabetes duration (years), mean (SD) | 6.50 (3.89) | 8.34 (7.74) |
| Body weight (kg), mean (SD) | 73.26 (12.91) | 71.33 (15.94) |
| BMI (kg/m2), mean (SD) | 26.44 (3.87) | 25.53 (4.21) |
| Diabetes complications, n (%) | 27 (39.7) | 33 (47.1) |
| Retinopathy | 8 (11.8) | 15 (21.4) |
| Neuropathy | 6 (8.8) | 13 (18.6) |
| Nephropathy | 17 (25.0) | 15 (21.4) |
| Nondiabetic complications, n (%) | ||
| Hypertension | 32 (47.1) | 33 (47.1) |
| Hyperlipidaemia | 47 (69.1) | 45 (64.3) |
| HbA1c (%), mean (SD) | 7.87 (0.83) | 8.18 (0.90) |
| FPG (mg/dL), mean (SD)1 | 166.3 (33.9) | 173.9 (30.4) |
| eGFR (mL/min/1.73 m2), mean (SD) | 83.9 (17.1) | 84.7 (15.6) |
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; SD, standard deviation; T + C, teneligliptin plus canagliflozin; T + P, teneligliptin plus placebo.
1
FPG: 1 mg/dL = 0.0555 mmol/L.